Trial Profile
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients with Relapsed Small Cell Lung Cancer (SCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary) ; Topotecan; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 17 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 17 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 12 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record (NCT01387386).